公开(公告)号：US20240131025A1

公开(公告)日：2024-04-25

申请号：US18500735

申请日：2023-11-01

申请人： Actinium Pharmaceuticals, Inc.

发明人： Dragan Cicic

IPC分类号： A61K31/496 ,  A61K51/10 ,  A61P35/02 ,  C07K16/28

CPC分类号： A61K31/496 ,  A61K51/1069 ,  A61P35/02 ,  C07K16/2803

摘要： This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets the cancer cell, wherein the amounts of BCL-2 inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death.

公开(公告)号：US11963957B2

公开(公告)日：2024-04-23

申请号：US17114376

申请日：2020-12-07

申请人： Buck Institute for Research on Aging ,  Unity Biotechnology, Inc. ,  Mayo Foundation for Medical Education and Research

发明人： Remi-Martin Laberge ,  Judith Campisi ,  Albert Davalos ,  Marco Demaria ,  Nathaniel David ,  Jan M. A. van Deursen ,  Darren J. Baker ,  Bennett G. Childs

IPC分类号： A61P9/10 ,  A61K9/00 ,  A61K31/404 ,  A61K31/4178 ,  A61K31/428 ,  A61K31/4375 ,  A61K31/495 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/728 ,  A61K45/06 ,  A61K47/36 ,  A61K47/68 ,  A61P11/00 ,  A61P25/28 ,  A61P27/02 ,  C12N5/00 ,  C12N15/113 ,  C12Q1/48

CPC分类号： A61K31/496 ,  A61K9/0048 ,  A61K9/0073 ,  A61K31/404 ,  A61K31/4178 ,  A61K31/428 ,  A61K31/4375 ,  A61K31/495 ,  A61K31/5377 ,  A61K31/728 ,  A61K45/06 ,  A61K47/36 ,  A61K47/6807 ,  A61P9/10 ,  A61P11/00 ,  A61P25/28 ,  A61P27/02 ,  C12N5/0081 ,  C12N15/113 ,  C12N2320/30 ,  C12N2501/999 ,  C12N2503/02 ,  C12Q1/485

摘要： Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

公开(公告)号：US20240115577A1

公开(公告)日：2024-04-11

申请号：US18261467

申请日：2022-01-14

申请人： THE SCRIPPS RESEARCH INSTITUTE

发明人： Michael J. Bollong ,  Peter G. Schultz ,  Sida Shao ,  Arnab Chatterjee ,  Jian Jeffrey Chen ,  Nan Zhang

IPC分类号： A61K31/522 ,  A61K31/40 ,  A61K31/403 ,  A61K31/4162 ,  A61K31/495 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/513 ,  A61K31/519 ,  A61K31/551 ,  A61K31/69 ,  A61P11/00

CPC分类号： A61K31/522 ,  A61K31/40 ,  A61K31/403 ,  A61K31/4162 ,  A61K31/495 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/513 ,  A61K31/519 ,  A61K31/551 ,  A61K31/69 ,  A61P11/00

摘要： The present disclosure relates to compounds. and to their pharmaceutical compositions. that inhibit dipeptidyl peptidase IV (DPP4). Hie compounds selectively promote the proliferation of alveolar type 2 cells (AEC2s) and are useful in therapeutic methods of treating diseases whose etiology. for example. derives from epithelial degeneration and maladaptive remodeling, such as pulmonary' diseases like idiopathic pulmonary fibrosis (IFF), acute respiratory' distress syndrome (ARDS), and infant respiratory' distress syndromes (IRDS).

公开(公告)号：US20240115564A1

公开(公告)日：2024-04-11

申请号：US18271588

申请日：2022-01-11

申请人： The Regents of the University of California

发明人： Gregory Ku

IPC分类号： A61K31/496 ,  A61K31/4709 ,  A61K31/48 ,  A61K31/7088 ,  A61P3/10

CPC分类号： A61K31/496 ,  A61K31/4709 ,  A61K31/48 ,  A61K31/7088 ,  A61P3/10 ,  A61K2039/505

摘要： Methods for treating diabetes are described. The methods include administration of a serotonin receptor 1F (HTR1F) antagonist, such as a substituted piperidine, methysergide, or methiothepin, to a subject in need thereof. Administration of the HTR1F antagonist can increase survival of pancreatic beta cells in conjunction with pancreatic islet transplantation. Methods for transplanting pancreatic islets to subjects such as diabetes patients are also described.

公开(公告)号：US20240115553A1

公开(公告)日：2024-04-11

申请号：US18135225

申请日：2023-04-17

申请人： Azevan Pharmaceuticals, Inc.

发明人： Michael J. BROWNSTEIN

IPC分类号： A61K31/422 ,  A61K31/4545 ,  A61K31/496 ,  A61P25/00

CPC分类号： A61K31/422 ,  A61K31/4545 ,  A61K31/496 ,  A61P25/00

摘要： Compounds, and compositions, methods, and uses thereof, are described herein for treating brain injuries.

公开(公告)号：US11951087B2

公开(公告)日：2024-04-09

申请号：US17813760

申请日：2022-07-20

申请人： Lanny Leo Johnson

发明人： Lanny Leo Johnson

IPC分类号： A61K31/192 ,  A61K31/14 ,  A61K31/205 ,  A61K31/496 ,  A61K47/10 ,  A61K47/26 ,  A61K47/60 ,  A61L12/12 ,  A61L12/14

CPC分类号： A61K31/192 ,  A61K31/14 ,  A61K31/205 ,  A61K31/496 ,  A61K47/10 ,  A61K47/26 ,  A61K47/60 ,  A61L12/12 ,  A61L12/141 ,  A61L12/143

摘要： This disclosure provides a method of treating an infection or inflammation of an eye of a mammal including contacting an eye with a solution comprising sterilized water and protocatechuic acid. The protocatechuic acid may be between about 0.01 wt % and 1.25 wt % in the solution. The solution may include saline. The solution may include ciprofloxacin and/or norfloxacin. This disclosure further provides a method of disinfecting a contact lens including contacting a contact lens with a solution including protocatechuic acid. The solution may include a surfactant. The surfactant may include polyethylene glycol esters of fatty acids, coconut, polysorbate, polyoxyethylene or polyoxypropylene ethers of high alkanes C12-C18. The surfactant may include poly(oxypropylene)-poly(oxyethylene) adducts of ethylene diamine having a molecular weight about 7,500 to about 27,000 wherein at least about 40 weight percent of the adducts is poly(oxyethylene).

公开(公告)号：US20240108616A1

公开(公告)日：2024-04-04

申请号：US18506606

申请日：2023-11-10

申请人： GENENTECH, INC. ,  HOFFMANN-LA ROCHE INC. ,  ABBVIE INC.

发明人： Deepak Sampath ,  Christian Klein ,  Wayne John Fairbrother ,  Sari L. Heitner Enschede ,  Rod A. Humerickhouse ,  Andrew W. Roberts ,  John F. Seymour

IPC分类号： A61K31/496 ,  A61K31/02 ,  A61K31/04 ,  A61K31/10 ,  A61K31/18 ,  A61K31/33 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/45 ,  A61K31/505 ,  A61K31/63 ,  A61K39/395

CPC分类号： A61K31/496 ,  A61K31/02 ,  A61K31/04 ,  A61K31/10 ,  A61K31/18 ,  A61K31/33 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/45 ,  A61K31/505 ,  A61K31/63 ,  A61K39/39558 ,  A61K2039/545

摘要： The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

公开(公告)号：US11945804B2

公开(公告)日：2024-04-02

申请号：US17743313

申请日：2022-05-12

申请人： Celgene Corporation

发明人： Matthew D. Alexander ,  Soraya Carrancio ,  Matthew D. Correa ,  Virginia Heather Sharron Grant ,  Joshua Hansen ,  Roy L. Harris ,  Dehua Huang ,  Timothy S. Kercher ,  Antonia Lopez-Girona ,  Mark A. Nagy ,  Veronique Plantevin-Krenitsky

IPC分类号： C07D403/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5377 ,  A61P35/00 ,  C07D401/04 ,  C07D401/14 ,  C07D407/14 ,  C07D417/14 ,  C07D491/08 ,  C07D491/10 ,  C07D491/107 ,  C07D498/08

CPC分类号： C07D403/14 ,  A61P35/00 ,  C07D407/14

摘要： Provided herein are 4-aminoisoindoline-1,3-dione compounds having the following structure:






wherein R, Ring A, and n are as defined herein, compositions comprising an effective amount of a 4-aminoisoindoline-1,3-dione compound, and methods for treating or preventing disorders.

公开(公告)号：US20240100033A1

公开(公告)日：2024-03-28

申请号：US18517512

申请日：2023-11-22

申请人： Aragon Pharmaceuticals, Inc.

发明人： Arturo Molina ,  Margaret Yu

IPC分类号： A61K31/4439 ,  A61K9/00 ,  A61K31/00 ,  A61K31/192 ,  A61K31/4152 ,  A61K31/4155 ,  A61K31/4166 ,  A61K31/4178 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4365 ,  A61K31/496 ,  A61P35/00

CPC分类号： A61K31/4439 ,  A61K9/0053 ,  A61K31/00 ,  A61K31/192 ,  A61K31/4152 ,  A61K31/4155 ,  A61K31/4166 ,  A61K31/4178 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4365 ,  A61K31/496 ,  A61P35/00 ,  G06Q30/0607

摘要： Described herein are methods of treating non-metastatic castrate-resistant prostate cancer using an approved drug product comprising apalutamide, enzalutamide or darolutamide. Also described here are drug products containing apalutamide enzalutamide or darolutamide, and methods of selling or offering for sale an anti-androgen drug product.

公开(公告)号：US20240091221A1

公开(公告)日：2024-03-21

申请号：US18372979

申请日：2023-09-26

申请人： Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro)

发明人： Pierre VANKAN ,  Andreea SASARMAN ,  Grasiela Bourscheit WILLMBRINK

IPC分类号： A61K31/496 ,  A61K47/10

CPC分类号： A61K31/496 ,  A61K47/10

摘要： This invention relates generally to therapeutic parenteral formulations comprising particular substituted pyridine based compounds, their manufacture, and methods and uses of said formulations in treating elevated intracranial pressure for indications such as, but not limited to, traumatic brain injury and stroke.